Bioprinting is a type of 3D printing to manufacture biological. So far, the process has been used to develop organs or organoidssmaller versions of organs that are at least partially functionaland can be used as models for research. Ultimately researchers hope they can bioprint organs that can be used for transplants.
Chicago-based BIOLIFE4D recently bioprinted a 3D miniature human heart, which they say is a big step toward producing a full-sized human heart that could be used for transplant. The company has research facilities at JLABS in Houston.
The miniature heart had all the structures of a full-sized heart, with four internal chambers. The company says it is as close as anyone has gotten to a fully functioning heart via 3D bioprinting.
We are extremely proud of what we have accomplished, from the ability to 3D bioprint human cardiac tissue last summer to a mini heart with full structure now, said Ravi Birla, the companys chief science officer. These milestones are a testament to the hard work of our team and the proprietary process we have developed that enables this type of scientific achievement. We believe we are at the forefront of whole heart bioengineering, a field that has matured quickly over the last year, and well positioned to continue our rapid scientific advancement. Today is an exciting day, but we continue forward earnestly toward the end goal of 3D bioprinting whole human hearts.
3D printing is sometimes called additive manufacturing. It is a way of making three-dimensional solid objects from a digital file. In many ways, the only limitations are the limits on the complexity of the design. 3D printing used in industrial applications typically use carbon fiber as a source material. But bioprinting uses a variety of biological materials, such as single cell suspensions, as the source materials.
In the case of BIOLIFE4Ds heart, they developed a proprietary bioink with a unique composition of different extracellular matrix compounds. These compounds are very similar to the properties of a mammalian heart. The company also developed a novel bioprinting algorithm made up of printing parameters optimized for the whole heart, which it coupled with patient-derived cardiomyocytes. Although the heart is small in size, it has many of the features of a human heart.
BIOLIFE4D isnt the only company working in this specific area. In April, researchers at Tel Aviv University successfully printed the first 3D human heart. The research team used the patients own cells and various biological materials such as collagen and glycoprotein. Their work was published in the journal Advanced Science.
This heart is made from human cells and patient-specific biological materials, stated Tal Dvir, lead researcher. In our process these materials serve as the bioinks, substances made of sugars and proteins that can be used for 3D printing of complex tissue models. People have managed to 3D-print the structure of a heart in the past, but not with cells or with blood vessels. Our results demonstrate the potential of our approach for engineering personalized tissue and organ replacement in the future.
Dvir and his team began by taking biopsies of fatty tissues from the omentum, a fold of visceral peritoneum that hangs from the stomach, in the abdomen of humans and pigs. They then separated the cellular materials from extraneous materials and reprogrammed the cellular materials to become pluripotent stem cells. From these, they were able to develop all three body layers that had the potential to produce any cell or tissue in the body.
They then built an extracellular matrix from collagen and glycoproteins into a hydrogel using the bioprinter. They mixed the cells with the hydrogel, which were then differentiated into cardiac or endothelial cells. This created what theyre calling patient-specific, immune-compatible cardiac patches complete with blood vessels.
From that point, they then created an entirebut smallbioengineered and bioprinted human heart.
Last year, Poietis, a Pessac, France-based company, along with Prometheus, a division of Skeletal Tissue Engineering at Leuven, Belgium, announced they had entered into a two-year Collaborative Research Agreement to develop high-precision 3D Bioprinting of tissue engineered Advanced Therapeutic Medicinal Products (ATMPs) for skeletal regeneration.
Prometheus focuses on tissue-engineered ATMPs with a focus on skeletal regeneration. Poietis is interested in using 3D bioprinting of single cell suspensions into large, patterned tissue structures, especially the laser-assisted bioprinting of multicellular micro-aggregates embedded in bioinks for the formation of layered cellular structures.
What this comes down to is a collaboration to print bone that can be used in transplants or other orthopedic, musculoskeletal or spine-related applications.
Poietis already has a product on the market, Poieskin, a human full thickness skin model produced entirely by 3D bioprinting. It is made up of a dermal compartment composed of primary human fibroblasts embedded in a collagen I matrix overlaid by a stratified epidermis derived from primary human keratinocytes.
In May, researchers with Rice University developed a new approach resulting in exquisitely entangled vascular networks that mimic the bodys natural passageways for blood, air, lymph and other vital fluids. The research was published in the journal Science.
One of the biggest roadblocks to generating functional tissue replacements has been our inability to print the complex vasculature that can supply nutrients to densely populated tissues, stated Jordan Miller of Rice University. Further, our organs actually contain independent vascular networkslike the airways and blood vessels of the lung or the bile ducts and blood vessels in the liver. These interpenetrating networks are physically and biochemically entangled, and the architecture itself is intimately related to tissue function. Ours is the first bioprinting technology that addresses the challenge of multivascularization in a direct and comprehensive way.
Also in May, San Diego-based Organovo entered a collaboration agreement with Melissa Little at the Murdoch Childrens Research Institute (MCRI), The Royal Childrens Hospital, in Melbourne, Australia, and Ton Rabelink at Universiteit Leiden (LUMC), Leiden, Netherlands. The collaboration will focus on expanding the use of 3D bioprinted stem cell-based therapeutic tissues. The goal is to develop treatments for end-stage renal disease.
The collaboration will utilize Organovos bioprinting platform, MCRIs advanced stem cell differentiation technology, and LUMCs cell lines and clinical expertise. The partnership is funded by Stem Cells Australia and CSL Limited.
And in 2018, United Therapeutics and Lung Biotechnology made a collaboration pact with Israeli 3D bioprinting company CollPlant. United paid CollPlant $5 million up front with up to $15 million in milestones to supply bioink to Lung Biotechnology. CollPlants recombinant human collagen (rhCollagen) is grown from tobacco plants engineered with five human genes. The purified collagen can be used as a scaffold for 3D bioprinting solid organs.
BIOLIFE4D has had several breakthroughs in this area. Earlier this year it successfully 3D bioprinted individual heart components, and in June 2018 it successfully 3D bioprinted a cardiac patch out of human cardiac tissue.
The companys 3D bioprinting process gives the researchers the opportunity to reprogram a patients own white blood cells to induced pluripotent stem (iPS) cells, then to force the iPS cells to differentiate into different types of cardiac cells to be used as individual cardiac components and eventually, into a human heart that could be used for transplant.
This is an incredibly exciting time for BIOLIFE4D, and we are so proud of Dr. Birla and the team for this tremendous accomplishment, said Steven Morris, the companys chief executive officer. We began this journey with an end goal of developing a technology that has the potential to save lives, and we are a step closer to that today. We will continue our work until we are able to 3D bioprint full-sized hearts for viable transplant, and change the way heart disease is treated forever.
- Global Induced Pluripotent Stem Cells Market to Achieve more Profitability Ratio between 2020-2025 - Chronicle 99 - February 16th, 2020
- Cell-based meat in focus: In conversation with Meatable, Finless Foods, New Age Meats - FoodNavigator-USA.com - February 11th, 2020
- Research could be step toward lab-grown eggs and sperm to treat... - ScienceBlog.com - February 10th, 2020
- First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News - February 10th, 2020
- Chromatin accessibility analysis reveals regulatory dynamics of developing human retina and hiPSC-derived retinal organoids - Science Advances - February 10th, 2020
- AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other... - February 4th, 2020
- 2020 Induced Pluripotent Stem Cells (iPSCs) Study: Global Markets, Technologies, Applications and Companies - Yahoo Finance - February 2nd, 2020
- Can Parkinsons be prevented as it stealthily develops? - Big Think - February 2nd, 2020
- Unpicking the proteome in single cells - Science Magazine - February 2nd, 2020
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Get rid of the ache within the nerves discovered with the following pointers, learn - Sahiwal Tv - January 25th, 2020
- Astellas and Adaptimmune team up in CAR-T development - European Biotechnology - January 15th, 2020
- Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 - Galus Australis - January 15th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Yahoo Finance - January 15th, 2020
- Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News - January 15th, 2020
- CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -... - January 10th, 2020
- Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald - January 10th, 2020
- Stem Cell Therapy Market Robust Growth Counted to 2025 - Instanews247 - January 10th, 2020
- The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub - January 10th, 2020
- Induced Pluripotent Stem Cells Market Structure, Industry Inspection, and Forecast 2025 - Filmi Baba - December 28th, 2019
- Top Technical Advances of 2019 - The Scientist - December 24th, 2019
- The next 3D-printing craze? It could be functioning 'mini-livers' - Inverse - December 24th, 2019
- Induced Pluripotent Stem Cells Market: Latest Innovations, Drivers and Industry Key Events 2016 2021 - Market Reports Observer - December 24th, 2019
- Stem Cell-Derived Cells Market Expected to Expand at a Steady CAGR through 2019 2029 - Downey Magazine - December 17th, 2019
- AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells - Yahoo... - December 11th, 2019
- Patent Granted To Lineage & AgeX - Anti Aging News - December 11th, 2019
- Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies - BioSpace - December 11th, 2019
- Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting - GlobeNewswire - December 11th, 2019
- Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy - Benzinga - December 8th, 2019
- Induced Pluripotent Stem Cells Market Assessed To Tell Apart High Growth By Implies In 2018 to 2026 - Wolf Mirror - December 5th, 2019
- Kyoto University Seeking To Use Stem Cells On Knee Treatment - Anti Aging News - December 5th, 2019
- Story of a 15-year old scientist: How it all began - EuroScientist - December 5th, 2019
- Stemonix, Atomwise Team Up on Drug Discovery With MicroOrgans and AI - Xconomy - December 5th, 2019
- Channel in Nerve Cell May be Key in Unlocking Parkinson Disease Therapy - Pharmacy Times - December 3rd, 2019
- First-in-kind Human 3-dimensional Models of Parkinson's Disease and Progressive Multiple Sclerosis Launching to the International Space Station -... - December 3rd, 2019
- Stem Cells Market 2019 Global Growth Analysis and Forecast Report by 2025 - Markets Gazette 24 - November 26th, 2019
- UK animal experiment statistics indicate reluctance to embrace modern tools to advance British labs into the 21st century - Labmate Online - November 10th, 2019
- Human heart cells change during spaceflight, say scientists in study that could have far-reaching effects on c - MEAWW - November 7th, 2019
- Here's Why Fate Therapeutics Dropped as Much as 19.9% Today - Motley Fool - November 7th, 2019
- Space travel may change the human heart - Inverse - November 7th, 2019
- Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Research and Develop Induced Pluripotent Stem Cell (iPSC)-Derived Allogeneic... - November 5th, 2019
- Goldfinch Bio to Present Oral and Poster Presentations at the American Society of Nephrology Kidney Week 2019 Annual Meeting - BioSpace - November 5th, 2019
- MD Anderson and Takeda Team Up on Next-Generation Immuno-Oncology Therapeutics - BioSpace - November 5th, 2019
- Induced Pluripotent Stem Cell Market is expected to witness a strong CAGR of 7.0% from 2018 to 2026 - Zebvo - November 2nd, 2019
- Can organoids, derived from stem cells, be used in disease treatments? - The Hindu - October 26th, 2019
- University team to seek approval for iPS-based heart treatment trial - The Japan Times - October 26th, 2019
- Global Gemcitabine Hydrochloride Market: Segmented By Application And Geography Trends, Growth And Forecasts To 2024 - Health News Office - October 26th, 2019
- Global consortium formed to combat unproven cell banking services - Drug Target Review - October 22nd, 2019
- Bloomberg Philanthropies, Johns Hopkins University School of Medicine, and The New York Stem Cell Foundation Research Institute Announce an... - October 22nd, 2019
- ISCT forms cell and gene therapy sector-wide coalition to combat the rise of unproven commercial cell banking services - PharmiWeb.com - October 21st, 2019
- Mutations Linked to Huntington's Increase Cells' Resistance to Manganese, Study Finds - Huntington's Disease News - October 15th, 2019
- Stem Cells Market : Insights Into the Competitive Scenario of the Market - Online News Guru - October 11th, 2019
- 'Rewind Therapeutics' and Remyelination - SciTech Europa - October 11th, 2019
- Cell Expansion Market is expected to rise at a remarkable CAGR during the Forecast Period 2016 2024 - Space Market Research - October 9th, 2019
- Global Induced Pluripotent Stem Cells Market 2019 Innovative Trends and Insights Research upto 2024 - News Adopt - October 5th, 2019
- New Rett Therapies May Stem From X-chromosome Reactivation Findings - Rett Syndrome News - October 5th, 2019
- Stemming the Tide of Alzheimer's - UCI News - October 5th, 2019
- Skin-Derived Heart Cells Help Uncover the Genetic Foundations of Cardiac Function - Technology Networks - October 5th, 2019
- IGIB finds a protein with better precision in gene-editing - The Hindu - October 5th, 2019
- Novel Cell Sorting and Separation Market: Focus on Acoustophoresis, Buoyancy-activated, Dielectrophoresis, Magnetophoretics, Microfluidics,... - October 5th, 2019
- Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications - Fabry Disease News - September 27th, 2019
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2019 Analysis & Forecast Report 2024 - Analytics News - September 24th, 2019
- Gene regulators work together for oversized impact on schizophrenia risk - National Institutes of Health - September 24th, 2019
- Blood Pressure and Prostate Treatment May Prevent or Slow Parkinson's, Early Study Suggests - Parkinson's News Today - September 24th, 2019
- New Gene Editing Technique Shown to Correct COL7A1 Gene in RDEB Cells - Epidermolysis Bullosa News - September 24th, 2019
- Vaginitis Therapeutics Market Overview with Detailed Analysis, Competitive lands - News By ReportsGO - September 24th, 2019
- Efavirenz/Tenofovir/Emtricitabine Combination Drug Market Overview with Detailed - News by Intelligence Journal - September 24th, 2019
- Can Consciousness be Created? - University Observer Online - September 24th, 2019
- Global Induced Pluripotent Stem Cells (iPSCs) Market 2019 Industry Growth with CAGR 12.7% in Forecast to 2024 - Indian Columnist - September 21st, 2019
- Adipose Tissue-derived Stem Cells Market Size Set for Rapid Growth and Trend by2018 2028 - My Health Reporter - September 21st, 2019
- Induced Pluripotent Stem Cell Market Estimated to be Driven by Innovation and Industrialization - Analytics News - September 20th, 2019
- 2024 Projections: Induced Pluripotent Stem Cells (iPSCs) Market Report by Type, Application and Regional Outlook - TheSlapClap - September 20th, 2019
- Angelman Foundation Honors 4 for Their Research, Advocacy Efforts - Angelman Syndrome News - September 20th, 2019
- Dicerna And DCR-A1AT In Alpha-1 Antitrypsin Deficiency-Associated Liver Disease - Seeking Alpha - September 20th, 2019
- Fate Therapeutics raises $173 million in offering - The San Diego Union-Tribune - September 19th, 2019
- Induced Pluripotent Stem Cells Market is expected to reach US$ 2299.5 Mn by the end of the forecast period in 2026 - Zebvo - September 19th, 2019
- induced pluripotent stem cells (iPSCs) market reached $2.1 billion in 2016 The market should reach $3.6 billion in 2021 - ScoopJunction - September 19th, 2019
- Stem Cell-Derived Cells Market to Record an Exponential CAGR by 2025 - NewsVarsity - September 19th, 2019
- Common Prostate Drug May Slow Progression of Parkinson, Researchers Say - AJMC.com Managed Markets Network - September 19th, 2019